Gubra A/S (CPH:GUBRA)
Denmark
· Delayed Price · Currency is DKK 356.00
-16.00 (-4.30%)
Apr 16, 2025, 4:59 PM CET
Gubra Employees
Gubra had 260 employees as of December 31, 2024. The number of employees increased by 40 or 18.18% compared to the previous year.
Employees
260
Change (1Y)
40
Growth (1Y)
18.18%
Revenue / Employee
1.02M DKK
Profits / Employee
-140.38K DKK
Market Cap
5.81B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 260 | 40 | 18.18% |
| Dec 31, 2023 | 220 | 26 | 13.40% |
| Dec 31, 2022 | 194 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 77,349 |
| Coloplast | 16,639 |
| Genmab | 2,682 |
| Demant | 22,639 |
| ALK-Abelló | 2,753 |
| Ambu A/S | 5,196 |
| Zealand Pharma | 335 |
| H. Lundbeck | 5,707 |
Gubra News
- 6 weeks ago - Healthy Returns: AbbVie is the newest potential weight loss drug market player - CNBC
- 6 weeks ago - AbbVie Steps Into The Ring In The Obesity Drug Wars - Seeking Alpha
- 6 weeks ago - AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - Benzinga
- 6 weeks ago - AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal - Investopedia
- 6 weeks ago - AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal - GuruFocus
- 6 weeks ago - AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. - Investor's Business Daily
- 6 weeks ago - AbbVie forays into obesity market with up to $2.2B Gubra license deal - Seeking Alpha
- 5 months ago - Danish Biotech Gubra Says Obesity Drug Positive in Early Trial - BNN Bloomberg